Peripheral Artery Disease Global Market Report 2024 Market Outlook Report 2024 | Size, Trends, Analysis, Insights, Overview By 2033

"The new report published by The Business Research Company, titled Peripheral Artery Disease Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the peripheral artery disease market size has grown strongly in recent years. It will grow from $3.97 billion in 2023 to $4.28 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The peripheral artery disease market size is expected to see strong growth in the next few years. It will grow to $5.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12068&type=smp

Rising Prevalence Of Peripheral Artery Diseases Expected To Drive Growth In Peripheral Artery Disease Market
The rise in the prevalence of peripheral artery diseases is expected to propel the growth of the peripheral artery disease market going forward. Peripheral artery disease refers to the narrowing or blockage of arteries outside the heart, usually in the legs, resulting in reduced blood flow and potential complications. Peripheral artery disease treatment helps reduce peripheral artery disease symptoms, enhance mobility, and decrease the risk of severe complications that improve patients' well-being. For instance, in April 2023, according to HMP Communications LLC, a US-based patient-centered education resource, the global prevalence of peripheral artery disease increased from 11.3 million in 1995 to 21 million in 2020 and estimated to reach 23.8 million by 2030. Therefore, the rise in the prevalence of peripheral artery diseases is driving the growth of the peripheral artery disease market.

Technologically Advanced Solution For Peripheral Artery Disease Treatment
Technological advancements are a key trend gaining popularity in the peripheral artery disease market. Major companies operating in the peripheral artery disease market are adopting technologically advanced surgery treatments to sustain their position in the market. For instance, in November 2022, Genesis MedTech Group, a Singapore-based medical device company, introduced chocolate touch paclitaxel DCB catheter, a percutaneous transluminal angioplasty (PTA) catheter for the treatment of patients with superficial femoral artery and popliteal artery disease. The Chocolate Touch drug-coated balloon is the first and only balloon catheter in the device that combines therapeutic agent administration with a next-generation angioplasty platform for treating peripheral artery disease. It uses pillow-like structures covered with a therapeutic chemical to open in tiny parts to offer an alternate therapy to standard drug-coated balloon angioplasty for individuals suffering from peripheral artery disease. As a result, the balloon surface increases, allowing for more effective medication delivery to the vessel wall and eliminating the requirement for permanent implants.

The peripheral artery disease market covered in this report is segmented -

1) By Type: Peripheral Angioplasty Balloons, Peripheral Stents, Peripheral Catheters, Inferior Vena Cava (IVC) Filters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Peripheral Accessories
2) By Drugs: Lipid-Lowering Drugs, Blood Pressure Lowering Drugs, Glucose Regulating Drugs, Blood Clot Preventing Drugs, Inotropes, Thrombolytics Agents, Anti-Inflammatory Agents
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By End Users: Hospitals, Specialty Clinics, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12068&type=discount

Major companies operating in the peripheral artery disease market report are Cardinal Health Inc., Vascular Solutions Inc., Bayer AG, Abbott Laboratories, Medtronic plc., Koninklijke Philips N.V. (Royal Philips), B. Braun Melsungen AG., Terumo Corporation, Edwards Lifesciences, Becton Dickinson and Company (BD), Boston Scientific Corporation Incorporated, Cook Group Incorporated, Merit Medical Systems Inc., NuVasive Inc., Arjo AB, Penumbra Inc., BIOTRONIK SE and Co. KG, Natus Medical Inc., AngioDynamics Inc., Shockwave Medical Inc., Cardiovascular Systems Inc., Endologix LLC., LeMaitre Vascular Inc., Silk Road Medical Inc., WL Gore and Associates Inc., MicroPort Scientific Corporation, Bard Peripheral Vascular Inc., Lombard Medical Inc., Avinger Inc., Ra Medical Systems Inc.

Contents of the report:
1. Executive Summary
2. Peripheral Artery Disease Market Report Structure
3. Peripheral Artery Disease Market Trends And Strategies
4. Peripheral Artery Disease Market - Macro Economic Scenario
5. Peripheral Artery Disease Market Size And Growth
…..
27. Peripheral Artery Disease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/peripheral-artery-disease-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.